PTC Therapeutics (PTCT) Receives Price Target

PTC Therapeutics (PTCT) : The highest level PTC Therapeutics (PTCT) is projected to reach is $20 for the short term and the lowest estimate is at $7. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $11.4 and the possibility the share price can swing is $5.03.

PTC Therapeutics (PTCT) : 6 analysts are covering PTC Therapeutics (PTCT) and their average rating on the stock is 2.67, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, Equity Analysts at the Citigroup maintains the rating on PTC Therapeutics (NASDAQ:PTCT). The brokerage firm has issued a Neutral rating on the shares. The Analysts at the ratings agency raises the price target from $8 per share to $9 per share. The rating by the firm was issued on August 8, 2016.

PTC Therapeutics (NASDAQ:PTCT): The stock opened at $8.20 on Thursday but the bulls could not build on the opening and the stock topped out at $8.20 for the day. The stock traded down to $7.75 during the day, due to lack of any buying support eventually closed down at $7.79 with a loss of -5.12% for the day. The stock had closed at $8.21 on the previous day. The total traded volume was 612,894 shares.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *